key: cord-0892038-kzcqgkmv
authors: Bhowmik, Deep; Sharma, Ravi Datta; Prakash, Amresh; Kumar, Diwakar
title: “Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL(pro) and PL(pro)."
date: 2021-02-15
journal: J Mol Struct
DOI: 10.1016/j.molstruc.2021.130094
sha: a7d5a8e21697cb04ee55c63ea3a407c43411e76b
doc_id: 892038
cord_uid: kzcqgkmv

The sudden increase in the COVID-19 epidemic affected by novel coronavirus 2019 has jeopardized public health worldwide. Hence the necessities of a drug or therapeutic agent that heal SARS-CoV-2 infections are essential requirements. The viral genome encodes a large Polyprotein, further processed by the main protease/ 3C-like protease (3CL(pro)) and papain-like proteases (PL(pro)) into 16 nonstructural proteins to form a viral replication complex. These essential functions of 3CL(pro) and PL(pro) in virus duplication make these proteases a promising target for discovering potential therapeutic candidates and possible treatment for SARS-CoV-2 infection. This study aimed to screen a unique set of protease inhibitors library against 3CL(pro) and PL(pro) of the SARS-CoV-2. A molecular docking study was performed using PyRx to reveal the binding affinity of the selected ligands and molecular dynamic simulations were executed to assess the three-dimensional stability of protein-ligand complexes. The pharmacodynamics parameters of the inhibitors were predicted using admetSAR. The top two ligands (Nafamostat and VR23) based on docking scores were selected for further studies. Selected ligands showed excellent pharmacokinetic properties with proper absorption, bioavailability and minimal toxicity. Due to the emerging and efficiency of remdesivir and dexamethasone in healing COVID-19 patients, ADMET properties of the selected ligands were thus compared with it. MD Simulation studies up to 100ns revealed the ligands' stability at the target proteins' binding site residues. Therefore, Nafamostat and VR23 may provide potential treatment options against SARS-CoV-2 infections by potentially inhibiting virus duplication though more research is warranted.

In December 2019, a new coronavirus caused an outbreak of the pulmonary disease in Wuhan, the capital of Hubei province in China, and has since spread globally [Wu et The ~306 aa long 3CL pro , a key enzyme for coronavirus replication, is also encoded by the polypeptide and responsible for processing the polypeptide into functional proteins Zhang et al., 2020] . The 3CL pro , also known as Nsp5, is the first to get automatically cleaved from polyproteins to produce mature enzymes, and then it further assists in the cleavage of downstream Nsps at 11 sites to release Nsp4-Nsp16 . 3CL pro directly mediates the maturation of Nsps, which is essential in the life cycle of the virus. Studies have shown that 3CL pro of different coronaviruses and all the 3CL pro cleavage sites on polyprotein 1ab are highly conserved in sequences and 3D structures [Yang et al., 2006; Xue et al., 2008] . Since there are no known human proteases with a similar cleaving specificity, 3CL pro inhibitors are less likely to be toxic and, together with its functional importance, have made 3CL pro an attractive target for the design of anti-SARS-CoV-2 drugs Xue et al., 2008; .

PL pro is responsible for the cleavages of N-terminus of the replicase polyprotein at three conserved cleavage sites to release Nsp1, Nsp2 and Nsp3, essential for correcting virus replication [Harcourt et al., 2004 ; Barretto et al., 2005] . PL pro was also confirmed to be significant to antagonize the host's innate immunity [Chen et Molecular docking has become a promising tool for drug discovery and development. By utilizing this tool, the binding interaction of drug-like molecules inside the target protein's binding pockets can be investigated with other factors like identification of hit molecules, optimization of lead compound and virtual screening. Since COVID-19 is a significant outbreak in 215 nations and there are no effective drugs for COVID-19, it is challenging to cure SARS-CoV-2 infection and control the associated pandemic. Therefore, novel drug design and discovery techniques can be utilized to discover potential therapeutic candidates against SARS-CoV-2.

The crystal structures for 3CL pro (PDB ID: 6Y2E, Resolution: 1.75 Å) and PL pro (PDB ID:6W9C, Resolution: 2.70 Å) of SARS-CoV-2 were downloaded from the PDB database (https://www.rcsb.org) in PDB format and were utilized for the in silico studies.

YASARA Energy Minimization Server carried out energy minimization of the crystal structures of 3CL pro and PL pro of the SARS-CoV-2 to obtain an energy-minimized and highly stable protein 

Binding site residues were anticipated through a literature survey for 3CL pro [Yang et al., 

Protease inhibitors, a class of antiviral drugs, are widely used to treat HIV/AIDS and hepatitis C.

Inhibition of serine proteases mitigated SARS-CoV pathogenesis in vivo was also reported.

Protease inhibitors prevent viral replication by selectively binding to viral proteases and blocking proteolytic cleavage of protein precursors necessary for the production of infectious viral particles [Patick et al., 1998 

Validation of docking protocol is essential in molecular docking to ensure that ligands bind in the correct conformation within the protein's binding site pocket, which is done by validating the PyRx, a virtual screening software for computational drug discovery, was used to screen the selected ligands (set of protease inhibitors) files against SARS-CoV-2 3CL pro and PL pro [Dallakyan& Olson, 2014] . PyRx uses AutoDock 4 and AutoDockVina as docking software implying the Lamarckian Genetic Algorithm and Empirical Free Energy Scoring Function. PyRx was carried out using selected inhibitors' on the energy minimized structure of SARS-CoV-2 3CL pro and PL pro . The macromolecular structure of two proteases (3CL pro &PL pro ) and the ligands were prepared and docking was accomplished into the binding site residues inside a grid box with X, Y and Z axis and dimensions adjusted to 16.17 Å × 17.25 Å × 20.14 Å and 49.43 Å × 49.41 Å × 21.06 Å for SARS-CoV-2 3CL pro and PL pro protein respectively. As in PL pro , the catalytic triad Cys111-His272-Asp286 in each of three subunits A, B and C respectively are 

The drug-likeness prediction of the selected ligands was carried out by Lipinski filter 

All-atoms MD simulations were performed on the atomic coordinates of the best-docked complex of SARS-CoV-2 target proteins, i.e., 3CL pro and PL pro using Gromacs v5. Ramachandran plot analysis showed that 99.6% residues are in favoured, allowed and generously allowed regions and only 0.4% in the disallowed region for the energy minimized 3CL pro protein.

In comparison, 100% residues are in favoured, additionally allowed and generously allowed regions for the PL pro protein (Fig. S1 ).

The top challenging job in computational chemistry is predicting ligands' actual binding conformation into protein binding sites [Azam et al., 2014] . After successful docking between the selected ligands (set of protease inhibitors) and the binding site of SARS-CoV-2 3CL pro and PL pro , the ligands' docking scores were noted and the best-ranked poses with the lowest docking score were chosen for interaction studies in detail. The mode of interaction of inhibitor compounds with amino acid residues in protein binding sites results in the compounds' binding affinity and potency [Zafar et al., 2020] .

The docking study carried out with the set of protease inhibitors as ligands against 3CL pro and PL pro of SARS-CoV-2 gave a formative revelation of molecular interplay. We find that all ligands interact with 3CL pro and PL pro more or less efficiently. Nafamostat and VR23 [7-chloro-4-(4-((2,4-dinitrophenyl)sulfonyl) piperazin-1-yl) quinoline] showed the lowest binding energy and high efficiency against both the target protein, i.e., 3CL pro and PL pro of SARS-CoV-2.

Nafamostat showed binding energy of -9.0 kcal/mol and -9.2 kcal/mol against 3CL pro and PL pro , respectively, while VR23 possessed binding energy of -9.1 kcal/mol against both 3CL pro and PL pro , respectively ( Fig. 1 & 2 , respectively.

The docking experiment was carried out in PyRx with grid box formation to include all the active site residues for SARS-CoV-2 3CL pro and PL pro . Further bond length, H-bond formation between ligands and target protein were analyzed using Ligplot and interactions were depicted in . Apart from these two residues, Nafamostat also forms H-bond with Thr26, while VR23 forms H-bond with Ser144 ( Fig. 3A-B) .

On the other hand, the 2D interaction of the selected protease inhibitors with SARS-CoV-2 PL pro revealed Nafamostat's interaction and H-bond formation with the residue Asp286 of the catalytic triad Cys111-His272-Asp286 of subunit C apart from other vital interactions with the binding site residues across other subunits (Fig. 3C) . VR23 did not form an H-bond with the catalytic triad Cys111-His272-Asp286 of any of the subunits of PL pro . However, VR23 was highly efficient in interacting with other binding site residues such as Trp106 and Ala288 of subunit C and Asn267 and Tyr273 of subunit A respectively, of PL pro (Fig. 3D ).

Lipinski's rule of 5 (http://www.scfbio-iitd.res.in/software/drugdesign/lipinski.jsp) predicted the selected molecular properties of the ligands from the SMILES imported from PubChem (Table S2) . As evaluated by molinspiration, the molecular property showed excellent results for both the selected ligands (protease inhibitors) to evaluate a single violation for both the inhibitors in Lipinski's rule of 5 ( Table 2) . The AB% (>50%) of a drug is a good sign for its excellent bioavailability, distribution and circulation by oral route [Ghose et al., 1999; Hebert et al., 2013] . Both Nafamostat and VR23 possessed AB% > 50% ( Table 2) .

The selected ligands' bioactivity was checked through molinspiration and calculated the activity against GPCR ligand, ion channel modulator, a kinase inhibitor, nuclear receptor ligand, protease inhibitors. The bioactivity prediction by molinspiration is tabulated in Table 3 .

The pharmacodynamic study for the selected ligands was carried out through admetSAR to understand the drug's action inside a host's body. The ADMET properties of the selected ligands revealed through admetSAR (http://lmmd.ecust.edu.cn:8000/) are presented in Table 4 . The Table 4 .

Molecular docking and pharmacokinetic analyses resulted in selecting two possible protease inhibitors, Nafamostat and VR23, against the SARS-CoV-2 protease proteins, 3CL pro and PL pro .

In order to examine the molecular stability of the inhibitor's interactions with viral proteases, the best docking poses were selected and all-atoms MD simulations were carried out for the period of 100 ns at the physiological temperature. The changes in the structural features underlying the protease-inhibitors interactions were analyzed through investigating the plots of RMSD, Rg, SASA, RMSF, H-bonds and potential energies, as shown in Fig. 4 

Cα-RMSD plot of inhibitors, Nafamostat and VR23 complexed with 3CL pro , during the simulation is depicted in Figure 4A . In this fig. 4A , we can see that the RMSD plot of the 3CL pro -Nafamostat complex reaches the steady equilibrium at ~30 ns. The initial rising in RMSD of ~0.15 nm during 0-25 ns indicates the structural perturbation to well-fit the inhibitor, which is gradually dropped at ~30 ns. The complex structure remains stable with RMSD 0.19±0.02 nm till the end of simulation at 100 ns. The RMSD plot of 3CL pro -VR23 shows that it also attains equilibrium at ~30 ns, after the initial deviation of RMSD ~0.10 ns; however, the structure is observed a stable RMSD value of 0.21±0.03 nm. The RMSD plot of the PL pro -Nafamostat complex suggested relatively stable conformational dynamics of protease-inhibitor, showing a steady equilibrium at RMSD 0.14±0.02 nm can be seen throughout the simulation time (Fig.   5A) . However, the binding of VR23 with PL pro shows the sharp drift of 2.0 nm, optimized at ~40

ns. This equilibrium state is prolonged up to 80 ns and the further increase in RMSD can be seen for the last 20 ns. The result shows that the structure of the PL pro -VR23 complex propagated with an average RMSD 1.89±0.60 nm. These findings indicate a stable global conformational dynamic of Nafamostatwith both proteases, 3CL pro and PL pro , and VR23 with 3CL pro . Whereas the binding of VR23 with PL pro underwent significant conformational changes.

Further, protease-inhibitors' conformation stability was determined by the radius of gyration (R g ), which defines the structural compactness of protein. The average Rg values for 3CL pro -Nafamostat, 3CL pro -VR23, PL pro -Nafamostat and PL pro -VR23 complexes were calculated as 2.19, 2.20, 2.32 and 3.32 nm, respectively ( Fig. 4B & 5B) . The R g plot shows a minor increase in R g values at 0-10 and 20-25 ns, which gradually settles around 30 ns in the Nafamostat docked structure with 3CL pro (Figure 4B ). The initial deviation in R g values may be considered the time taken to optimize Nafamostat'swell-fitting at the binding pocket of 3CL pro . After that, no structural drifts were observed in the R g trajectory of 3CL pro -Nafamostat, suggesting the complex's stability for the remaining period of simulation 30-100 ns. Protease-inhibitor interactions. The R g plot of PL pro -Nafamostat quickly attains the stable equilibrium and is observed consistently throughout the simulation time ( Figure 5B) . The slight deviation in the R g plot of 3CL pro -VR23 can be seen during the 0-30 ns, which attained equilibrium at ~30 ns and the structural integrity of the complex is observed stable for the simulation time 30-100 ns.

Remarkably, the R g plot of PL pro -VR23 shows a sharp drift of ~0.75 nm at ~15 ns, which settles gradually around ~40 ns and a stable R g trajectory is seen up to 100 ns. The substantial jump in R g values may be due to the significant conformational changes before accommodating the inhibitor at the binding pocket of PL pro . Thus, the significant deviation in R g values and a slow rate to achieve equilibrium suggested a less stable conformational dynamics of PL pro -VR23 than the binding of VR23 with 3CL pro . Moreover, a better equilibrated and stabilized structure of Nafamostat with both 3CL pro and PL pro , respectively.

The changes in protease-inhibitor complexes' structural features have also been analyzed by computing the solvent-accessible surface area (SASA (Fig. 5C) . Thus, comparing the binding of inhibitors with proteases, it is observed that Nafamostat has stable molecular interaction with 3CL pro and PL pro .

Eventually, the binding of VR23 with 3CL pro also provides evidence of stable molecular interactions. However, the molecular interaction of VR23 with PL pro indicates the orientational change in the protein surface; thus, we observed a higher value for the accessible area of PL pro -VR23.

To examine protease-inhibitor interactions' dynamic progression, we calculated the root mean Fig. 4D shows that the binding of inhibitors with protease 3CL pro complies with a stable molecular interaction and displays almost completely overlapping RMSF plots for 3CL pro -Nafamostat and 3CL pro -VR23. The much higher deviation in the RMSF plot of PL pro -VR23 can be observed compared to PL pro -Nafamostat (Fig. 5D) . The residues of 3CL pro belonging to the stable secondary structure of α-helices and β-sheets display average atomic fluctuations <0.25 nm and no significant perturbation is observed for the region belonging to loops. Indeed, the binding pocket residues (Ser1, Glu166, Thr26 & Ser144) having lower atomic fluctuation, which evident in the stable molecular interaction of inhibitors with 3CL pro . We also find the consistent molecular interaction of Nafamostat with PL pro (Figure 5D) .

However, the RMSF plot of PL pro -VR23 shows the overall higher atomic fluctuations for all residues. Interestingly, the lower atomic fluctuation for residues (Trp106, Ala288, Asn 267 &Tyr273), involved in the interaction with VR23, clearly indicates that ligand remains occupied at the binding pocket during the simulation and higher RMSF is observed due to the conformational shifting of protease, PL pro .

More importantly, we computed the time evolution plot of hydrogen bonds' occupancy (Hbonds) between target proteases and inhibitors. H-bonds play a crucial role in maintaining the shape and stability of protein structure and govern the protein-ligand molecular interactions. Fig.   4E shows that the maximum propensity of three H-bonds between 3CL pro and VR23. Among them, only one H-bond remains consistent and two appeared and disappeared transiently. The molecular interaction of 3CL pro with Nafamostat displays two H-bonds, which can be seen up to ~65 ns. However, one H-bond is lost during the last ~35ns of simulation. The H-bond interactions of inhibitors with PL pro is shown in Fig. 5E . Figure 5E shows Nafamostat's structure is stabilized at the binding pocket of PL pro through four H-bonds, out of which two are observed consistently during the simulation.

On the other hand, we find the propensity of single H-bond interaction between VR23 and PL pro , which appears intermittently. Thus, H-bond interactions, along with structural parameter analyses described in Fig. 5A -D, provide clear evidence of the loosely bound structure of VR23 with PL pro . Finally, we measured the potential energy of inhibitor bound complexes of 3CL pro and PL pro . Fig. 4F shows that the structure of 3CL pro -Nafamostat and 3CL pro -VR23 have potential energy values -7.60×10 5 and -7.87×10 5 kJ/mol, respectively. Whereas the structure of PL pro -Nafamostat and PL pro -VR23 shows the potential energy values -1.30×10 5 and -1.03×10 5 kJ/mol (Fig. 5F) . Thus, the obtained higher potential energy values for inhibitors bound complexes of 3CL pro compared to complexes with PL pro suggested the higher molecular affinity of Nafamostat and VR23 towards 3CL pro . This result also indicates Nafamostat's higher molecular affinity with PL pro than VR23, showing approximately 2.7×10 5 kJ/mol higher potential energy.

The MD simulation analyses collectively revealed a higher structural stability of Nafamostat with both proteases, 3CL pro and PL pro . Moreover, VR23 shows preferably stable molecular interaction towards 3CL pro as compared to PL pro . This study provides the structural insights of the molecular interaction of identified inhibitors, Nafamostat and VR23, against the two significant proteases of SARS-CoV-2, 3CL pro and PL pro , which can be explored as a potential lead in the development of anti-CoV drug therapy to control the pandemic of COVID-19.

Our study revealed that Nafamostat and VR23 interact with the critical binding site residues of 3CL pro and PL pro of SARS-CoV-2 and probably inhibit the growth of SARS-CoV-2 by targeting 3CL pro and PL pro . Pharmacokinetics properties matching the required criteria for drug-likeness and Nafamostat and VR23 may be considered a potential drug against SARS-CoV-2. Proteinligand complexes for 3CL pro and PL pro were structurally stable throughout the 100 ns simulation period concerning distance and fluctuation dynamics. However, further experimental studies are needed to check the possible preclinical and clinical efficacy of Nafamostat and VR23 to prevent and treat SARS-CoV-2.

The authors declare that no conflict of interest exists. 

GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

Pharmacological studies of FUT-175, nafamstatmesilate. I. Inhibition of protease activity in in vitro and in vivo experiments

Potential inhibitorsagainst papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs

Potential of heparin and nafamostat combination therapy for COVID-19

Comparative modeling and virtual screening for the identification of novel inhibitors for myo-inositol-1-phosphate synthase

The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity

… ACTT-1 Study Group Members (2020). Remdesivir for the Treatment of Covid-19 -Preliminary Report

The missing term in effective pair potentials

Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. Infection, genetics and evolution :journal of molecular epidemiology and evolutionary genetics in infectious diseases

Evaluation of potential drugs against leishmaniasis targeting catalytic subunit of Leishmaniadonovani nuclear DNA primase using ligand based virtual screening, docking and molecular dynamics approaches

SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Small-molecule library screening by docking with PyRx

Particle mesh Ewald: An N⋅ log(N) method for Ewald sums in large systems

Protease inhibitors for the treatment of hepatitis C virus infection

A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity

Impact of Pregnancy on Maternal Pharmacokinetics of Medications

LINCS: A linear constraint solver for molecular simulations

From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design

Effect of dexamethasone in hospitalized patients with covid-19: preliminary report

Mechanism of the maturation process of SARS-CoV 3CL protease

Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus

Pharmacological studies of FUT-175, nafamostatmesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats

Inhibition of SARS-CoV 3CL protease by flavonoids

Dexamethasone in the management of covid -19

Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations. The journal of physical chemistry

A Synthetic Serine Protease Inhibitor, NafamostatMesilate, Is a Drug Potentially Applicable to the Treatment of Ebola Virus Disease. The Tohoku journal of experimental medicine

Open Babel: An open chemical toolbox

Characterization of heterogeneous intermediate ensembles on the guanidinium chloride-induced unfolding pathway of β-lactoglobulin

Crystal Structure and Pair Potentials: A Molecular-Dynamics Study

Protease inhibitors as antiviral agents

Elucidation of stable intermediates in urea-induced unfolding pathway of human carbonic anhydrase IX

Insilico study of the A 2A R-D 2 R kinetics and interfacial contact surface for heteromerization

VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification

Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery

The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease

The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain

Delineating the conformational dynamics of intermediate structures on the unfolding pathway of β-lactoglobulin in aqueous urea and dimethyl sulfoxide

Structural basis of SARS-CoV-2 3CL pro and anti-COVID-19 drug discovery from medicinal plants

In Vitro Absorption Studies and Their Relevance to Absorption from the GI Tract

Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges

LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Ebselen as a highly active inhibitor of PLproCoV2

Discovery of potent inhibitors of PL pro C oV2 by screening a library of selenium-containing compounds

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

A new coronavirus associated with human respiratory disease in China

Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

Design of wide-spectrum inhibitors targeting coronavirus main proteases

Drug design targeting the main protease, the Achilles' heel of coronaviruses

Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay

The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner

p53 degradation by a coronavirus papain-like protease suppresses type I interferon signaling

Zinc metal carboxylates as Potential anti-Alzheimer's candidate: In-vitro anticholinesterase, antioxidant and molecular docking studies

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Rate-limited steps of human oral absorption and QSAR studies

A pneumonia outbreak associated with a new coronavirus of probable bat origin

SwissParam: a fast force field generation tool for small organic molecules

Log S (>-4)